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ABSTRACT Growing demand for customized pharmaceu-
tics and medical devices makes the impact of additive manu-
facturing increased rapidly in recent years. The 3D printing
has become one of the most revolutionary and powerful tool
serving as a technology of precise manufacturing of individu-
ally developed dosage forms, tissue engineering and disease
modeling. The current achievements include multifunctional
drug delivery systems with accelerated release characteristic,
adjustable and personalized dosage forms, implants and phan-
toms corresponding to specific patient anatomy as well as cell-
based materials for regenerative medicine. This review sum-
marizes the newest achievements and challenges of additive
manufacturing in the field of pharmaceutical and biomedical
research that have been published since 2015. Currently de-
veloped techniques of 3D printing are briefly described while
comprehensive analysis of extrusion-based methods as the
most intensively investigated is provided. The issue of printlets
attributes, i.e. shape and size is described with regard to per-
sonalized dosage forms and medical devices manufacturing.
The undeniable benefits of 3D printing are highlighted, how-
ever a critical view resulting from the limitations and chal-
lenges of the additive manufacturing is also included. The
regulatory issue is pointed as well.
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ABBREVIATIONS
3DP Three-dimensional printing
ABS Acrylonitrile butadiene styrene
AM Additive manufacturing
API Active pharmaceutical ingredient
CAD Computed aided design
CT Computed tomography
dcDU Dual-compartmental dosage unit
DLP Digital light projector
DOD Drop on drop
DOS Drop on solid
DPPO Diphenyl(2,4,6-trimethylbenzoyl)phosphine
oxide
EC Ethyl cellulose
FDA Food and Drug Administration
FDM Fused deposition modeling
HIPS High impact polystyrene
HME Hot melt extrusion
HPC Hydroxypropyl cellulose
HPMC Hydroxypropyl methylcellulose
HPMCAS Hydroxypropyl methylcellulose acetate succinate
MRI Magnetic resonance imaging
ODF Orodispersible films
PCL Polycaprolactone
PDMS Polydimethylsiloxane
PEG Poly(ethylene glycol)
PEGDA Poly(ethylene glycol) diacrylate
PET-G Polyethylene terephthalate glycol-modified
PLA Polylactic acid
PVA Poly(vinyl alcohol)
PVP Polyvinylpyrrolidone
RP Rapid prototyping
SLA Stereolithography
SLM Selective laser melting
SLS Selective laser sintering
SPPC Scanning printing polishing casting
Tg Glass transition temperature
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INTRODUCTION
There is a constant motivation towards new concepts in drug
design, better understanding of material properties, manufac-
turing technology and processes that assures high quality of
dosage forms. The diversity of physicochemical and biophar-
maceutical characteristics of active pharmaceutical ingre-
dients (APIs) have to be considered and studied through each
stage of product development. Auxiliary substances need to be
examined as well in order to manufacture of the desired dos-
age form.
Within last decade the patient-centric drug product devel-
opment has been under considerable attention. It was focused
on novel dosage forms and technological processes. Growing
demand for customized devices combined with an expansion of
technological innovation drives the major progress in personal-
ized medicine expressed e.g. by the production of small series of
individually-selected doses and tailor-made prostheses meet the
anatomical needs of patients. Within many discoveries intro-
duced into pharmaceutical and biomedical market, three-
dimensional printing (3DP) is believed to be the most revolu-
tionary and powerful. This technique is recognized as a versatile
tool of precise manufacturing of various devices. It serves as a
technology for developing novel dosage forms, tissues and
organs engineering as well as disease modeling.
Nowadays, three-dimensional printing is one of the fastest
developing branch of technology, art and science, and still
broadens the applications. The term three-dimensional print-
ing was defined by International Standard Organization (ISO)
as: Bfabrication of objects through the deposition of a material
using a print head, nozzle, or another printer technology^. In
contrast to commonly used subtractive and formative manufac-
turing methodologies, this technique is one of the methods of
additive manufacturing (AM) in which the parts are prepared
from 3Dmodel data in the process of joining materials layer by
layer. The practical approach of AM is called rapid prototyping
(RP) (1) and its advantages include the reduction of prototyping
time and costs, easy modifications of a product at a designed
level, the possibility of manufacturing of small objects, individ-
ualized product series or structures impossible to be formed
with subtractive techniques (2).
The application of 3D printing in the science and engineer-
ing has grown since 2012. The number of scientific papers
recorded in Web of Science Core Collection containing a
term B3D printing^ or B3D printed^ in the title increased
from 59 in 2012 to 1573 in 2017. Moreover, the number of
citations of these papers in the same period grown from 209 to
12,411. Narrowing the searching results to the category of
pharmacy/pharmacology gives no result in 2012, however
77 records were found up to 2017, which also shows a great
interest in the 3DP methods in pharmaceutical sciences.
This review is aimed at the newest development and achieve-
ments in the field of pharmaceutical and biomedical research
from the literature items that have been published within the last
3 years. The novel approaches in the formulation of solid dosage
forms for individualized therapy are particularly focused, how-
ever transdermal drug delivery as well as biomedical applications
of additive manufacturing technique including implants, surgical
models, bioprintedmaterials and biorobotics are alsomentioned.
The parallel development of additive manufacturing used in
pharmaceutical technology and bioprinting is summarized and
compared with a special effort made to point out the evolution of
bioprinting. Due to the fact that the pharmaceutical applications
of additive manufacturing is on the early stage of development
and implementation not many regulatory is available however
the important issues that have been introduced by the FDA in
2017 are mentioned.
A BIT OF HISTORY
The idea of 3DP has evolved from early 70′ of the twentieth
century when Pierre A. L. Ciraud described the method of
application of powdered material and subsequent solidifica-
tion of each layer through the action of high energy beam. In
this case meltable materials such as plastics or metals can be
theoretically used for object preparation. In early 80′ in a
patent entitles: BA molding process for forming a three-
dimensional article in layers^, Ross Housholder described an
idea of sand binding by different materials and Carl Deckard
developed a method of solidification of powdered bed by laser
beam called selective laser sintering (SLS).
The first commercially available technology created by
Chuck Hull was stereolithography (SLA). This method was
based on photopolymerization of liquid resin by ultraviolet
light. At the end of 80’s Scott Crump filed a patent for fused
deposition modelling (FDM) – a technique which used ther-
moplastic material for object preparation. In the 90’s
Emanuel Sachs - MIT scientist with co-workers patented
BThree-dimensional printing techniques^ based on joining
the selected regions of powder by binding material (3). The
most important achievements in 3D printing in pharmaceuti-
cal and biomedical applications are presented in Fig. 1.
HOW IT WORKS
Among almost 40 years of 3DP history many different techni-
ques were developed and evolved with the technological
progress.
The main methods are based on:
& powder solidification,
& liquid solidification,
& extrusion.
176 Page 2 of 22 Pharm Res (2018) 35: 176
Schematic view of 3DP methods applied for drug formu-
lation is presented in Fig. 2.
Each 3D printer which works according to a different
mode requires sufficient material to be solidified and subse-
quent object fabrication (Fig. 3).
Despite of the diversity of 3DP methods, preparation of
3D-printed object includes several stages:
& the design of 3D object with computer-aided design soft-
ware and optimization of the geometry according to print-
er specification,
& the export of 3D model to a common and printer-
recognizable file format e.g. STL which includes only
3D geometry in form of each vertex position data or
OBJ in which additionally information about polygonal
faces or color texture are coded,
& the import of the file to the software and generation of
layers which will be printed; the height of the printed layer
essentially influences the quality of the printed object as
well as printing time,
& the fabrication of the object by subsequent application (or
solidification) of the material layers dedicated to the spe-
cific printing method.
The development of 3D printed object is illustrated in
Fig. 4.
The 3D printingmethods gain an importance in the field of
pharmaceutical and medical applications because of the pos-
sibility of rapid preparation of tailor-made objects which can
be applied in personalized therapy ormedicine. The introduc-
tion of 3D printing into the pharmaceutical technology par-
ticularly aims at the development of patient-centered dosage
forms based on structure design. It is still a new research di-
rection with potential to create the targeted release drug
Fig. 1 The most important achievements in 3D printing in pharmaceutical
and biomedical applications.
Fig 2 3DP methods applied for drug formulation.
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delivery systems in freeform geometries. Extensive research
are conducted for oral dosage forms because that route of
administration still remains the major and the favorite one.
Some investigations are also focused on dosage forms for top-
ical administration. The examples of 3D printed products
demonstrate the growing interest in drug design by using dif-
ferent 3D printing techniques (Table I, Fig. 5).
From Powder it will Raise
The first 3DP method used in the development of pharma-
ceutical dosage forms was based on the idea presented in
patent entitled BThree-dimensional printing techniques^ (3).
The printing process mode of action is similar to desktop inkjet
printers and is called drop on solid deposition –DOS or pow-
der bed jetting. Droplets of ink sprayed from print head bind
the layer of free powder bed while unbound powder particles
act as a support material preventing from collapsing of over-
hang or porous structures. After each step the formed object is
lowered and a layer of free powder is applied by roller or
powder jetting system and process is proceeded (Fig. 6).
The first printers were equipped with commercially avail-
able thermal or piezoelectric print heads that delivered bond-
ing agent. Active pharmaceutical ingredients as well as mod-
ifying agents can be either dissolved or dispersed in ink or
distributed in powder bed. This method was used due to its
similarity to classical formulation processes as wet granulation
and the ability to apply the excipients commonly used in the
Fig 3 3D printing methods.
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field of pharmaceutical technology, especially in solid dosage
form formulations. One of the advantage of this method is
possibility of precise location of exact dose of drug or
modifying excipients within powdered bed to obtain several
compartments with different composition or mode of action.
The product quality attributes are influenced by powder and
ink properties. The layer height is mainly influenced by
particle size and flowability of powder bed as well as
cohesion force between particles and part of the printer or
powder wettability. Lower layer height and subsequent layer
application result in more detailed and precise fabrication of
objects with minor mass and dose variations. The ink
constituents as solvents, APIs or modifying excipient can
change viscosity, droplet size and influence the efficiency of
powder binding. The process parameters as printing speed,
droplet volume, distance from powder bed also play an
important role in the product development and can have an
impact on the powder bonding especially between layers in Z
axis. They may negatively affect the mechanical strength of
the printlets. After printing, additional steps as drying, residual
solvents and unbound powder removal should be performed.
The DOS method was used in preparation of various solid
systems such as implants with levofloxacin (16) or in combina-
tion with rifampicine (41), rifampicine and isoniazid (42)
exhibiting modified or pulsatile release of APIs. The chlorphe-
niramine tablets with modified release () and acetaminophen
tablets with linear release profiles () were developed as well.
The DOS method is suitable for preparation of easily dis-
integrating tablet with porous structure. The development in
this filed have led to the commercialization of ZipDose® tech-
nology by Aprecia® Pharmaceuticals and the first 3D-printed
drug Spritam®which was approved in 2015 by FDA (43). The
orodispersible tablets which disintegrate within seconds in
aqueous solution contain antiepileptic drug levetiracetam. In
case of orodispersible tablets high dose of APIs usually results
in technological problems in manufacturing and quality con-
trol (44). Application of 3DP techniques allowed to prepare
fast disintegration tablets with dose up to 1000 mg (45).
Example of Spritam® showed that DOS can be used in a
large scale manufacturing of highly porous ODTs.
Nevertheless, preparation of multicomponent modified re-
lease tables on large production scale with sufficient repeat-
ability of quality attributes can be challenging with regard to
more dense structure of this tablets compared to ODT.
Variations in porosity resulted from the differences in adhe-
sion between layers can influence the APIs dissolution profile.
The application of higher amount of binder prolongs drying
time and increases the risk of limited removal of residual
solvent.
A powder can be also solidified by applying the beam of
high energy. The basic construction assumptions of selective
laser sintering or selective laser melting (SLM) are similar to
DOS method. Powdered bed is transferred from one com-
partment to another by levelling system and layers are formed
by sintering (heating just below melting temperature) or melt-
ing the polymeric or metallic powdered bed by laser beam
(Fig. 7).
In this process the high energy beam is created usually by
laser and applied power varies depending on powder
properties. While 5 W laser is sufficient in case of polyamide,
even 1 kW laser is required for metal melting. Powder bed
must be heated before printing in the printer chamber to the
temperature adequate to the process parameters. After
printing the fabricated objects are imbedded in powder and
the bed should be slowly cooled down to avoid stress. These
steps are time consuming and depends on printer chamber
Fig. 4 The development of 3D printed object (from ref. (4) with modification).
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volume. Another drawback is the risk of API decomposition
after exposure to laser beam. Despite all the disadvantages,
the SLS method is under consideration as a way of solid
dosage form formulation. Fina et al. () used SLS for prepara-
tion of paracetamol tablet with Kollicoat® IR or Eudragit®
L100–55. Additionally, Candurin® gold sheen was added to
aid the sintering process. The produced printlets were char-
acterized by good mechanical properties - low friability in the
range of 0.02–0.56% and high crushing strength - from 284 N
to over 485 N. The drug content was equal to the theoretical
Table I Examples of 3D Printed Medicines Prepared with Different 3D Printing Methods
Manufacturing method Dosage form API Excipients Effect Ref.
Powder solidifcation
Drop on solid Implant Isoniazide Powder:
PLLA
Ink:
Acethone,
Ethanole,
Water
Sustained release (5)
Tablets Captopril Powders:
maltitol,
maltodextrin,
Ink:
Water
Polyvinylpyrrolidone
Rapidly dispersing tablets (6)
Selective laser sintering Orodispersible
tablets
Paracetamol hydroxypropyl
methylcellulose
vinylpyrrolidone-vinyl acetate
copolymer
Orodispersible tablets, fast
drug release
(7)
Liquid solidification
Stereolithography Tablets Paracetamol
4-
Aminosalicylic
acid
Poly(ethylene glycol) diacrylate,
Poly(ethylene glycol) 300,
diphenyl(2,4,6-
trimethylbenzoyl) phosphine
oxide
Co-
ntrolled release
(8)
Microneedles Insulin Dental SG
resin
Xylitol,
Mannitol,
Trehalose
Insulin skin delivery
(9)
Drop on drop Tablets Ropinirole
HCl
Irgacure 2959
Poly(ethylene glycol) diacrylate
Fickian diffusion API release
mechanizm
(10)
Tablets Fenofibrate White beeswax Fickian diffusion API release
mechanizm
(11)
Extrusion based methods
Fused deposition modelling Orodispersible
films
Aripiprazole Polyvinyl alcohol Fast disintegration and
dissolution
(12)
Tablets Theophylline Hydroxypropyl cellulose,
Triacetin,
Sodium starch glycolate,
Croscarmellose sodium,
Crospovidone,
Immediate release (13)
Extrusion at room
temperature
Floating tablets Dipyridamole Hydroxypropyl methyl cellulose,
Microcrystalline cellulose,
Lactose,
Polyvinyl pyrrolidone
Sustained release, gastrofloating
dosage form
(14)
Multi-compart-
ment
tablet
Nifedypine,
Captopril,
Glipizide
Polyethylene glycol 6000, Microcrystalline
cellulose,
Hydroxypropyl methylcelloluse,
D-Mannitol, Lactose, Sodium starch glycolate,
Croscarmellose sodium, Sodium chloride,
Tromethamine
Controlled release (15)
176 Page 6 of 22 Pharm Res (2018) 35: 176
value. The pH-independent release characteristics with the
release rate dependent on the drug content were observed
for Kollicoat®-based formulations whereas Eudragit®-based
formulations showed pH-dependent and modified-release
profiles not correlated with the drug loading. The application
of another polymers i.e. hydroxypropyl methylcellulose or
Kollidon® VA 64 and optimization of printing parameters
influenced printlets characteristics. Increased laser scanner
speed resulted in more porous structure and decreased me-
chanical strength. In case of Kollidon® VA 64 printlets
showed fast dissolution characteristics (over 90% after 5 min)
and rapid disintegration time - 4 s (7).
SLS technology can be a promising method to obtain po-
rous, rapid disintegrating as well as modified release dosage
forms without binding agent. The decomposition of APIs may
be induced by high energy beam especially during prepara-
tion of more dense form. The stability issues and production
time seem to be important challenges in SLS application.
Sintering speed influencing the porosity of the printlets and
effectiveness of printing process can be increased by multipli-
cation of laser beams like in metal sintering 3D printers.
Turning Liquid into Solid
The idea of object manufacturing by solidification of liquid is
similar to powder solidification technique. Droplets of Bink^
sprayed from the nozzle are deposited on the thin layers and
cured by cooling air or in presence of high energy light. Due to
the absence of powdered bed the drop on drop (DOD) or
Polyjet technology requires the use of additional material to
create support for overhang geometries. The print head
moves along X and Y axes during printing, the print platform
bed is lowered along Z axis by the height of the layer after the
deposition of each layer of the material (Fig. 8). Different
Fig. 5 Examples of 3D printed
products developed by different
3DP methods with references in
brackets.
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technical solutions applied in this technique resulted in possi-
bility of multi-material full-color printing.
The quality of printed product as well as curing method
depend on properties of spraying material. The first materials
used in this techniques were waxes. In pharmaceutical tech-
nology they were used in modified release dosage form
formulation and at present time also found application in
3DP technology. Molten wax was sprayed on build platform
in heated chamber to prevent rapid solidification. Matrix
tablets containing beeswax and fenofibrate were prepared by
Kyobula et al. (11) by means of 3D material jetting of molten
wax and the influence of bespoke geometries (honeycomb
architecture with different infill ratio) on dissolution profile
was revealed. The cell diameter of the honeycomb geometry
and material wettability were found to affect the dissolution
profile from tablets of constant weight. The amount of re-
leased drug increased with honeycomb diameter and surface
in case of middle size honeycomb channels. For the smallest
dimension of honeycomb, penetration of dissolution medium
was insufficient whereas surface of tablets with widest honey-
comb was smaller than middle size structure what resulted in
decreasing of drug dissolution in both cases. This phenomena
can allow the production of personalized medicines when ap-
plied with combination of different materials of various
geometry.
Photosensitive polymers can be also used in this techniques
and solidification of the layers is achieved by UV light. To
Fig. 6 Mechanism of DOS 3D printing (from ref. (4) with modification).
Fig. 7 SLS and SLM technology.
Fig. 8 DOD deposition technology.
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assess the possibility of photopolymer resin application in 3D
printing of drugs, tablets with ropinirole HCl, poly(ethylene
glycol) diacrylate (PEGDA) and Irgacure 2959 as photoinitia-
tor were prepared in an environment with low content of
oxygen which can inhibit the curing transformations.
Average printing time of tablets of 14 mg mass having
5.02 mm in diameter and 0.72 mm in height was ca. 4 min.
Crosslinking of UV-sensitive material resulted in formation of
amorphous solid dispersion of ropinirole HCl exhibiting sus-
tained release of API from tablet up to 6 h (10). In this tech-
nique post-process removal of unbounded polymer and pho-
toinitiator is important step. Toxicity of the components
should be considered when this process is applied in drug
formulation.
This first attempts of DOD method application in drug
formulation field revealed that tested matrix materials are
suitable in prolonged release dosage forms fabrication.
Challenging process of adaptation of a wide range of polymers
needs to be evaluated. The modification in wax matrix com-
position or application of hydrophilic polymers may have a
great impact on dissolution behavior. In case of solidification
method based on UV light, possibility of APIs decomposition
and stability matters should be taken into account. The post-
processing of dosage form as well as the toxicity and removal
of unbounded monomer and photoinitiator should be also
considered when this process is applied in drug formulation.
Photosensitive liquid polymers are also used in stereolithog-
raphy. The object is built by solidification of subsequent layers
of resin in the presence of high energy light e.g. UV laser beam
or light from projector (digital light projector - DLP). Laser
beam guided by scanner mirrors precisely Bdraws^ layers of
the object on build platform by cross-linking of the photopoly-
mer. In DLP techniques projector displays image of the whole
layer. Printed object is bound to the build platform which is
immersed in the photopolymer and layer is tracing on the
surface of the resin. Subsequently, platform descends a dis-
tance equal to the thickness of a single layer and sweeper
recoats object surface (Fig. 9).
In inverted SLA, source of light is situated under transpar-
ent bottom of a resin tank which is coated with a non-sticking
material. Build platform is lowered from above to the distance
equal to layer height and object layer is solidified. In the next
step object is raised and sweeper cleans tank bottom. This
mode of action allows to efficiently use the resin and
smoother layer surface. Wang (8) used polyethylene glycol
diacrylate as a resin and diphenyl(2,4,6-trimethylbenzoyl)-
phosphine oxide (DPPO) as photoinitiator to evaluate the
suitability of stereolithography (SLA) to fabricate 4-
aminosalicylic acid and paracetamol-loaded tablets with
modified-release characteristics. Tablets containing different
amount of polyethylene glycol 300 (PEG 300) were success-
fully printed and increasing PEG300 content revealed
enhancement of drug release within 10 h dissolution studies.
Martinez et al. () used also PEGDA as polymer but try to
evaluate possibility of application of the nontoxic photoinitia-
tor – riboflavin to obtain ibuprofen containing hydrogels with
different water content. Hydrogels containing up to 30% w/
w of water, and 10% w/w of ibuprofen, were successfully
printed. Dissolution profiles showed that drug release was
faster from hydrogels with higher water content.
The challenges in SLA application are similar to photo-
polymerization DOD method and are related to stability
and safety issues. Additionally, in SLA method the objects
are printed with solid infill and modification of porosity can
be obtained only by changing the geometry of the tablet.
Principles of Extrusion-Based Methods
Hot melt extrusion (HME) as well as extrusion of semisolid
materials are well established processes in the field of pharma-
ceutical technology. Increasing popularity of printingmethods
based on this technical solution is related to progressive avail-
ability of compact size and relatively inexpensive equipment.
Essentially two modes of printing method can be
distinguished:
& extrusion of semisolid, or semi-molten materials (gels,
pastes) at room or elevated temperature,
& extrusion of molten thermoplastic rod-shape material
(filament).
Fig. 9 SLA technology.
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In bothmodes the material is extruded from the nozzle and
spread in subsequent layers on the surface of build platform
(Fig. 10). Defined dimension of printed path is created by the
distance of print head to the build plate and influenced by the
nozzle orifice diameter. These two parameters and print
speed affect the quality of printed object. Another layer is
applied when print head or print platform moves along Z axis
at the distance of layer height. The 3D printers technological
solution are depending on printing material.
Filament – The Major Challenge
The fused deposition modelling is based on extrusion of mol-
ten thermoplastic material. Dimensions of filaments in the
range of 1.75 mm and 2.85–3 mm are adopted to standard
commercially available print heads. Standard filaments are
made of thermoplastic polymers such as acrylonitrile butadi-
ene styrene (ABS), poly(lactic acid) (PLA), high impact poly-
styrene (HIPS), polyethylene terephthalate glycol-modified
(PET-G), nylon. There are some commercially available
high-quality filaments processed from medically grade poly-
mers such as PLA, PVA, nevertheless the filaments prepared
from pharmaceutical grade polymers and containing APIs are
not commercially available so far. To prepare drug-loaded
filaments the thermal stability of impregnated API must be
considered. In FDM process the filament guided by gears is
moved towards heat end where it is melted and pushed
forward through the nozzle orifice by unmelted filament.
The diameter of the nozzle orifice varies from 0.2 to
0.4 mm, and has an impact on resolution of printed object.
Usually the printed path width is equal to the orifice diameter
and the height of the path is a half of its width, however the
final settlements can vary depending on the printed material
and printer settings. The paths are organized in layers and
formed into the object which resolution depends on layer
height. The mechanical parameters of the printed object are
related to number of outlines which build the external wall of
the object and infill parameters ratio and type (e.g. honey-
comb or rectilinear).
The filament quality attributes like constant dimension,
elasticity, stiffness, homogenous drug distribution are of the
key importance in the development of printed dosage form
by using FDM method. Nowadays, HME is a main way to
obtain good-quality filaments containing APIs, however the
first attempts of FDM method application were based on
ready-to-use, commercially available filaments for 3D print-
ers. Model drugs were incorporated into the filaments by
swelling filament in volatile solvent solution of API and drying.
This approach allowed to prepare first 3D-printed dosage
form by FDM method. Nevertheless, the drug content in the
filaments prepared in this way ranged from 0.063 to 0.3% for
ethanolic solutions (46) and 1.9% for methanolic soaking sol-
utions (47) what was a limitation in higher dosage form fabri-
cation. The simplest solution of this problem was a re-
extrusion of shredded or milled commercially available fila-
ment with APIs by HME. This process is designed to result in
filaments with higher drug content and mechanical properties
suitable for 3DP (46,48). Li Q. et al. (14) used this method for
preparation of PVA-based filament containing 5% of glipi-
zide. The development of dosage form formulation requires
high quality pharmaceutical grade excipients which can be
used in extrusion process. The excipients that meet the extru-
sion requirements should be characterized by proper glass
transition temperature (Tg), i.e. lower than drug decomposi-
tion temperature, matrix forming capability and good rheo-
logical properties. Therefore, the printability of raw materials
requires a deep understanding of the printing process, taking
into account physical and chemical characteristic changes
during its selection. As a result of HME process filaments with
sufficient mechanical attributes should be obtained because
during printing process filaments are bended and compressed
between feeding gear and driving gear. Very brittle filaments
can be broken by the gears whereas too soft filaments may be
squeezed aside by the feeding gear. Zhang et al. tested differ-
ent polymers: HPC, HPMC, EC, Soluplus®, Eudragit® L100
and combination of thereof as filament formers in HME pro-
cess. The 3-point bend test was used to assess the mechanical
properties of the prepared filaments and the results were com-
pared with data obtained for PLA commercially available
filaments. This approach allows to recognize borderFig. 10 Extrusion-based techniques.
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parameters and indicates which filament can be printable (49).
The properties of starting materials for filament fabrication
have a great impact on their printability, therefore the selec-
tion of appropriate HME-based matrices is required (50).
Different matrix polymers, plasticizers and fillers were used
to improve printability while lubricants were essentially used
to reduce friction between filament and walls of the printing
extruder (51). As a result ofmulticomponent formulation, high
drug-load filaments with good mechanical properties can be
obtained. Goyanes et al. (52) prepared filaments containing
50% of paracetamol based on HPMCAS with addition of
methylparaben as plasticizer andmagnesium stearate as lubri-
cant. Drug loading in filaments depends on properties of APIs
and excipients as well as the extruder construction and process
parameters. High theophylline and metformine-loaded fila-
ments were obtained by Verstraete et al. (). Different grades
of hydrophilic and hydrophobic thermoplastic polyurethane
were used as a matrix formers and filament with 60% of APIs
was obtained. High content of crystalline drug resulted in
rough surface of the filament which was reduced by milling
of APIs prior to the extrusion process. After milling filament
with consistent diameter, smooth surface morphology and
good mechanical properties were obtained. The predefine
printing parameters were found to influence printlets behav-
ior. The infill ratio which varied from 25 to 100% had an
impact on dissolution behavior of API. The decrease in drug
dissolution with increased infill ratio was correlated with de-
creasing porosity. However, layer height from 200 to 400 μm
as well as outline counts from 1 to 3 of printed tablets had no
influence on drug dissolution profiles. The influence of infill
ratio on dissolution profiles were reported in several publica-
tions (53). In case of paracetamol 5 and 50%-loaded tablets
the influence of infill on dissolution profile was also observed.
Additionally, the application of different grades of entering
coating polymer (HPMCAS) as matrix forming polymer
resulted in delayed dissolution profile characteristics. The
drug amount released after 2 h in acidic medium did not
exceed 10%. By combination of infill ratio and different
grades of polymers the modified release dosage forms with
different dissolution profiles were prepared (52).
Geometry Matters
The printlets shape also influences the drug dissolution rate.
Paracetamol tablet of different shapes with constant surface
were proposed by Goyanes et al. (). The fastest dissolution
rates were obtained for pyramid shape formulations which
has the biggest surface area/volume ratio whereas the cylin-
drical or spherical shapes with smallest surface area/volume
ratio were characterized by the slowest dissolution ratio.
Modification of tablet geometry by addition of the extra chan-
nels was also proposed to accelerate hydrochlorothiazide dis-
solution. Squared, in cross section, channels with diameter
ranging from 0.2 to 1.0 mm were imbedded during designing
stage. The dissolution data revealed that channel of size
≥0.6 mm essentially accelerated the drug release which meets
pharmacopoeial criterion for immediate release products ().
Another innovative approach of tablets was proposed by
Arafat et al. Tablets were composed of bridged 9 units with
spacing gaps. The different block and gaps size influenced the
disintegration and dissolution time. The designed approach is
an interesting alternative to disintegrants application to accel-
erate tablet disintegration (13).
Two Heads Are Better than One
In dual head extrusion process, the print head is equipped
with two separate stepper motors and heating compartment
which allows to carry out the process with two materials
characterized by different melting temperature. Okwuosa
et al. (51) prepared the delayed release tablets with theophyl-
line loaded core, based on PVP polymer, printed by one ex-
truder and outer complementary shell of Eudragit® L with
increasing thicknesses from 0.17 to 0.87 mm which was pre-
pared by second printing extruder. The shell thickness which
was required to achieve sufficient core protection in the acidic
medium was ≥0.52 mm.
Dual head solution can be also used to fabricate dual layer
modified release tablets. Li et al. () proposed concept of
DuoTablet – dosage form built with two (inner and outer)
compartments. The core of the tablet as well as the outer shell
were printed with glipizide-loaded PVA filament containing
different ratio of API, 4.8 and 2.2%, respectively. The disso-
lution studies revealed modifications of drug release profiles in
comparison to the tablets printed with one placebo compart-
ment. This approach can be a promising method of controlled
drug delivery system preparation.
Dual head printer was also used in fabrication of another
dosage form: dual-compartmental dosage unit (dcDU) which
is a two compartment tube printed with insoluble PLA.
During printing of the first compartment of the tube the pro-
cess was paused and tube was manually filed with rifampicine
or isoniazid loaded filaments. Printing process was continued
and paused when the second compartment was finished to
manually load the filament containing the other drug.
Sealing PVA cap was printed on the one side of the tube at
the end of the printing. The construction of the unit provides
the separation of incompatible APIs in single dosage form and
differentiation of dissolution profiles which shows lag time as a
result of cap seal (). Placebo structures influencing the dissolu-
tion profile were also proposed by Maroni et al. ().
Commercially available PVA filament as well as filaments
prepared by HME with pharmaceutical grade polymers
(Kollicoat® IR, HPMC, HPMCAS) were used to fabricate
three parts of dual compartment capsular device which two
hollow parts could be filled extemporaneously with different
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content and connected with the joining part. The polymers
used for the device preparation and wall thickness of the
hollow parts (600 or 1200 μm) resulted in modulation of bi-
modal released profile.
One of the advantage of FDM method is the possibility of
API amorphization during printing or HME filament prepara-
tion. API can be melted and/or dissolved in polymer matrix
according to the polymer properties and process parameters
and this phenomena may improve drug dissolution rate (54).
Aripiprazole-containing orodispersible films (ODF) prepared
by FDMwere compared with casted films. Drug in casted films
was crystalline whereas in printed films was fully amorphous on
account of two step hot melt extrusion (filament fabrication and
3D printing) what positively improved the dissolution profile of
aripiprazole from 3D-printed films. This study showed that
FDM is a technique that can be used as alternative to common-
ly used for the preparation of ODFs (12).
Extrusion-based methods are very promising. They provide
easy modification of the infill structure of the printlets, whereas
other techniques (SLA, SLS) require new 3Dmodels. However,
during filament aging undesirable interactions between fila-
ment components and variation in moisture content can lead
to changes in physical stability e.g. recrystallization of API. This
can impact mechanical properties of filament and results in
increased fragility or some shifts in melting temperature what
can negatively affect the properties of printed dosage form.
Extrusion of Semisolids
In case of printing of semisolid, or semi-molten materials (gels,
pastes) at room or elevated temperature by extrusion process,
some changes have been implemented in print head construc-
tion in comparison with FDM. The mass is extruded through
orifice by compressed air pressure, syringe plunger or screw.
This systems allow to fabricate high drug load dosage forms,
nevertheless after printing the drying step is required what can
influence the product integrity. Immediate release paraceta-
mol tablets with 80% of drug load were prepared with phar-
maceutical grade excipients that comply with pharmacopoeial
standards (). The systems with modified release were prepared
as well. Li Q et al. (14) developed gastro-floating tablets with
dipyridamole to prolong the gastric residence time. In vitro
buoyancy study revealed that 30 and 50% of infilling rate
formulations floated up to 12 h. Multi-syringe printing system
allows to prepare Bpolypill^ as multi-active solid dosage form
containing 3 or 5 APIs released with different kinetic charac-
teristics (15,).
PATIENT-CENTRIC THERAPY
Due to the possibility of various materials utilization, 3D print-
ing methods have wide range of applications in medicine e.g.
to build spatial systems used in tissue engineering as well as in
pharmacy to prepare such dosage forms as tablets (55), cap-
sules (), implants (,56) or orodispersible films (12). As already
mentioned, tablets are the most frequently produced dosage
forms. While they can be manufactured in several geometries,
very few doses for one API are available on the industrial scale
(15,57).
The idea of more individualized pharmacotherapy has
been developed for many years, however its meaning has nev-
er been greater as at present time. The need for developing
personalized medicine by rational use of drugs by the patients
in right dose is a subject of intensive discussion because het-
erogeneous nature of diseases is the source of difficulties in
therapeutic intervention. The therapy failures or limitations
of therapeutic effects are some of the reasons to modify the
dosage form as well as dose of the active substance especially
for individual age groups. The appropriate dosage forms need
to be selected considering not only physicochemical properties
but particularly target population and treated disease. The
development of pharmaceutical product for pediatric and ge-
riatric population is especially recommended due to the di-
verse needs and characteristic of each patient group. Due to
the dose flexibility and difference in swallowing, tablets subdi-
vision into two or even four parts is a common practice in
health care. The problems with scored tablets has been
reported in the literature. Unequally breaking and loss of mass
after division finally could lead to over- or under dosing (58).
Therefore, the implementation of three-dimensional printing
may became extremely useful in the development of person-
alized therapy.
The 3D printing allows to individualize medicine to the
patient body weight and lifestyle by dose and dosage form
adjustment, e.g. orodispersible tablets instead of conventional
tablets for active or noncompliant patients. The simplicity of
preparation of the medicines with different doses is caused by
the scalability of the designed objects, thus the dose can be
controlled by calculated material consumption during resizing
of the printed object already at the design stage. This manu-
facturing method seems to be especially beneficial in the pro-
duction of orphan drugs made for small groups of patients.
Relatively low cost of production of dosage forms with differ-
ent doses is one of the major advantage in term of short series
of medicinal product (15,57).
The 3D printing brings unprecedented opportunities for
the development and preparation of personalized medicines
at pharmaceutic or industrial scale. The introduction of 3D
printers to the hospitals and community pharmacies would
raise the pharmaceutical compounding to entirely new level.
Especially in case of pediatric patients not only the dose of the
active ingredient is important but also the quantity of the
administered medicines, their shape, color and taste play a
huge role in therapy (59). Moreover, in some 3D printing
methods, like fused deposition modelling, where APIs are
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incorporated into polymer matrix, taste masking is achievable
without any further processing such as film coating. Using this
3D printing method Scoutaris et al. () printed taste-masked
dosage forms in the shape of Starmix® Haribo jelly beans with
indomethacin with good reproducibility, accuracy, content
uniformity, and fast dissolution of the API. The size and the
shape of the tablet affect patient acceptability, especially in
term of swallowing difficulties. Tablet shape is also of crucial
importance to the elderly patients not only due to the
swallowing problems but also in accordance with the
manipulating problems. Goyanes et al. (60) investigated the
influence of different tablet shapes i.e. sphere, torus, disc, cap-
sule and tilted diamond shape on the patients feelings in term
of the ease of swallowing and handling. It was found that the
easiest to swallow were doughnut shape i.e. torus tablets. The
tablets of conventional shape were also defined as acceptable
because of their similarity to standard dosage forms. In the
previous studies the same team stated that this shape differ-
ences slightly influence the dissolution behavior so there
should be a freedom of choosing the geometry for individual
patients (). The effect of geometry and internal structure on
the printed dosage forms properties is a separate issue and it
was discussed in the FDM section of this article.
The 3D printing gives the opportunity for producing tab-
lets with more than one active substance characterized by
different properties and with different dissolution profiles.
Thus, it can result in the reduction of the amount of used
products by formulating complex medicines (61). By using of
3D printing technology the precise control over dissolution
behavior can be achieved mainly by applying selected soluble
or non-soluble excipients but also by designing the specified
geometry and internal structure of the printed dosage forms
(62). Nevertheless, this opportunity should only be used by
healthcare professionals because it requires the knowledge
about pharmacokinetics of the active substance and health
condition of the patient and it could be applied in hospital
pharmacies.
Although the solid oral dosage forms have been the most
widely studied, the 3D printing was also utilized to fabricate
transdermal drug delivery system. Luzuriaga et al. (63) printed
microneedles with fluorescein. Additional etching step was
necessary to achieve satisfactory microneedles shape. In the
latest research on microneedles stereolithography was applied
to obtain needles with appropriate shape and size and inkjet
print was carried out to coat the microneedles with insulin
formulation. The authors obtained rapid in vitro dissolution
of insulin but the most important was the possibility to pro-
duce microneedle patches in a simple way (9). The use of
microneedles can assure painless transdermal delivery of drugs
and vaccines, however themanufacturing technologies are still
difficult to apply in pharmaceutical industry (64).
Nevertheless, 3D printing is promising method of fabrication
of different microstructures.
The additive manufacturing methods were used to pro-
duce other topical delivery systems. Vaginal rings for con-
trolled topical delivery of progesterone were successfully man-
ufactured by J. Fu et al. (39) by fused deposition modelling.
The authors emphasized that particular drug delivery device
is strongly needed to be personalized due to the different needs
of the patients and a lack in the market of such personalized
vaginal delivery systems.
From Patient Home to Production Scale
The 3D printing of the medicines in patient facilities is
intensively discussed in the scientific communities but
additive manufacturing techniques are still rather new
for the society and vision that patients will print their
medicines in their own houses is rather faraway perspec-
tive. The main obstacle to the implementation of this
method to the patients is drug quality and safety issue.
Patients or their medical care have to be thoroughly
trained how to use printer and how to recognize quality
defects that may appear in their self-printed drug.
However, this approach can be beneficial for the
patients as a higher involvement in the treatment pro-
cess which was found to be clinically beneficial (65). On
the other hand, it can also lead to some disadvantages
like loss of control over adverse effects when formulating
polypills with many active substances within one
medication.
As it was mentioned before 3D printing can be relatively
easy introduced into the pharmaceutical compounding in the
pharmacies. Fused deposition modelling seems to have the
nearest way because having good quality of API loaded fila-
ment and database with objects to print, medically-educated
staff i.e. pharmacist can print the final dosage form with de-
fined architecture and dose of the active substance (65). The
manufacturing of API-loaded filaments is not a big challenge
for pharmaceutical industry because hot melt extrusion, which
is the basic method of filament preparation, is well established
in the pharmaceutical manufacturing. Printable filaments
have been obtained so far from number of pharmaceutical
grade polymers, i.e. cellulose derivatives, methacrylic acid
copolymers, poly(ethylene oxide), poly(vinyl alcohol), poly(vi-
nyl alcohol)-poly(ethylene glycol) graft copolymer, poly(vinyl
caprolactam)-poly(vinyl acetate)-poly(ethylene glycol) graft co-
polymer, poly(ethylene glycols), ethylene vinyl acetate and
others (12,50, 38). One of the advantages of this 3D printing
method is the possibility to produce filaments with incorpo-
rated API in crystalline state, which can be disordered during
extemporaneous 3D printing. This approach can overcome
the stability issue of amorphous drugs which are frequently
formed during 3D printing because of the mechanism of the
3D printing process which is often based on melting of API
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with polymer or fast evaporation of the solvent from drug
solution (66).
The introduction of 3D printing into the pharmaceutical
industry as a standard manufacturing method is still far away
from present mainly because of the lack of ready-made pro-
duction equipment. However, trends have been set by the first
registered and marketed 3D-printed drug production method
developed by Aprecia® Pharmaceuticals. In this industrial
scale pharmaceutical printing technology the formation of
tablets is carried out by repeated cycles of building layers by
the one feeding, liquid applying system on a conveyor (67).
However, this is not the only possibility, other potential meth-
od could be the use of a number of print heads, and in case of
powder bed bonding powder feeding zones, strictly
corresponding to the number of layers of the tablet on a
moving platform. In conventional 3D printers single nozzle
is used to print whole object. Taking into account that one
tablet is printed often for more than 1 min the effectiveness of
such method is very limited. In this methods object has to be
removed after printing and afterwards the printing process
can be repeated. The printing on a conveyor is faster and
eliminates the need for moving the nozzle in the Z axis
because successive print heads can be fixed higher by layer
height. One thing is certain, without developing equipment
designed especially for pharmaceutical applications 3D
printing will be still in the research phase and will not get to
the pharmacotherapy. Tranfield et al. (68) gives directions
what should characterize the ideal pharmaceutical 3D printer
and emphasizes that only the collaborative work of 3D printer
manufacturers, scientists, excipient suppliers and pharmaceu-
tical regulators can result in developing the ideal 3D printer.
LETTER OF LAW
Three-dimensional printing is rapidly growing technology
that is characterized by the high potential from the pharma-
ceutical point of view Although it is still at the initial stage of
considerations, many attempts have been made to scale up
this technology and 3DP has become a successful method
especially in personalized medicine. However, comprehensive
research is still necessary to make the 3DP techniques indus-
trially feasible for dosage form formulation. Nowadays, only
one FDA-approved product is on the market. The printable
products must comply with the current manufacturing and
control standards for the medical products and devices.
Current research shows both benefits of 3D printing technol-
ogy and its limitations. Therefore, due to the large number of
the factors affecting the quality of computationally designed
dosage forms and safety of their use, the appropriate regula-
tory requirements are very desirable. Nowadays, there are no
valid regulations concerning design, manufacturing process
and quality testing considerations. There is a strong need to
make some regulations for this particular group of manufac-
turing methods. Food and Drug Administration guidance re-
leased in December 2017, entitled Technical Considerations
for Additive ManufacturedMedical Devices gives the number
of guidelines considering the main aspects from software and
hardware requirements, quality control up to process valida-
tion procedures (69). As it is highlighted in the FDA document
due to variability of additive manufacturing methods there is
no possibility to give one universal set of guidelines for all of
the 3D printing methods. For example, processes such as SLS
and FDM cannot be compared because of different starting
materials, i.e. powder for SLS and filament for FDM, different
process parameters, i.e. laser beam energy, powder bed tem-
perature etc. for SLS and extrusion and printing platform
temperature for FDM technology. There are also some differ-
ences in post-processing in the printing methods: some of
them, i.e. selective laser sintering, stereolithography or drop
on solid methods require removing of manufacturing material
residues while the other methods like fused deposition model-
ling or drop on drop method do not. It seems that every single
printing method needs separate regulatory. It has to be under-
lined that there are still no regulations on medicinal products
which are often more demanding than the requirements for
medical devices. All of mentioned issues for devices should be
considered in case of medicines as well. Moreover, the pres-
ence of API makes much more aspects have to be taken into
account such as possible incompatibilities, active substance
stability during printing process etc. This is of crucial impor-
tance because fused deposition modeling method utilizes high
temperature twice, i.e. at the filament extrusion stage and
even higher temperature during printing. The possibility of
active substance amorphization and its stability as well as the
influence on the product properties have to be tested and
those should be specified in relevant guidelines.
It is expected that 3D printing will enter the pharmacother-
apy sooner or later in one of the described options. If so, there
is also a strong need to train the specialists in pharmaceutical
3D printing. Both physicians and pharmacists teaching pro-
gram should be extended by the topics concerned with addi-
tive manufacturing methods and their application in the
patients treatment.
(BIO)MEDICAL APPLICATIONS
The impact of additive manufacturing on biomedical field has
increased rapidly since the 3D printing was developed in the
early 80′. It is due to the fact that the technique enables for-
mation of individually developed materials of customized ar-
chitecture and functionalities. It evolved into powerful tool for
biomedical engineering providing formation of manufactur-
ing implants that correspond to patient-specific anatomy,
phantoms for education and surgical planning and disease
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models (Fig. 11). Moreover, additive manufacturing learns
from the nature what leads to formation of smart materials
or devices.
Wound Dressing
Growing demand for tailor-made functionalizedmaterials has
become a driving force for the development of additively man-
ufactured structures. Nanotechnological approaches address
many of challenges faced by modern medicine, however the
safety of their use is still under intensive investigation.
Although such approaches provide application of antibacteri-
al nanoparticles and carriers of factors improving the wound
healing, they are difficult for industrial application. It opens a
new challenging field for additive manufacturing as a tech-
nique sufficient to produce personalized and safe materials
of complex architecture and functionalities.
The manufacturing of patient-specific antimicrobial
wound dressings made from polycaprolactone (PCL) with in-
corporated zinc, copper and silver was described byMuwaffak
(). The metal-homogeneously-loaded filaments were obtained
using hot melt extrusion and 3Dmodels of nose and ears were
printed. The wound dressings exhibited prolonged release of
the different metals and bactericidal properties. The anatom-
ically adaptable dressings were concluded to be more afford-
able than conventional flat dressings.
The 3D-printed hybrid scaffold based on poly(ethylene gly-
col) (PEG) and homogenized pericardium matrix was devel-
oped in order to promote wound healing in vascular grafts
that can support the replacement of injured vessel wound after
surgical reconstruction (70). The incorporation of homoge-
nized pericardium into PEG matrix affects the modulus of
the scaffold as well as reduces the inflammatory signal of mac-
rophages. The obtained biomaterial was described as very
promising in terms of vascular graft development and opening
a new field in congenital heart defect reconstruction.
Implants and Prostheses
The fabrication of implants and prostheses by additive man-
ufacturing has recently revolutionized the area of developing
of medical devices fulfilling the growing demand for person-
alized therapy. The 3D printing enables preparation of tailor-
made products that meet individual needs resulted from spe-
cific patient anatomy and pathology. Moreover, it provides
the development of structures of site-specific mechanical and
physical properties as well as spatial and temporal control of
bioactive components.
The custom prosthetics attachments and devices enable to
restore mobility and functions as well as normal appearance
lost by deformations or traumas. Simple prosthetic foot was
developed by Herbert and coworkers (71). Authors demon-
strated that 3D printing is a simple and efficient technology of
fabrication of prosthetic sockets that patients after amputation
find comfortable. Another example was demonstrated by
Zuniga who prepared low-cost 3D-printed hand for children
with upper-limb reductions (72). Performed survey concluded
that the prosthesis may have positive impact on the quality of
life and can be applied for several activities in school and at
home.
The 3D-printed structures may also help patients in revi-
talization and faster recovery after bone fractures as Cortex
exoskeletal cast designed by Jake Evill. This orthopedic device
in form of nylon mesh was light, durable and breathable, and
what was described as the most important – water resistant
(73).
Additive manufacturing is of particular attention in cranio-
facial reconstructive surgery as individual face features can be
Fig. 11 Biomedical applications of 3D printing.
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precisely replicated what strongly affects physical appearance
and aesthetic issue. Congenital or traumatic deformities of
ears are commonly replaced by silicone prosthesis or patients
cartilage, however it is expensive and usually involves several
visits in hospital. Moreover, it is difficult to obtain the shape
that perfectly fit to the defect site without additional fillers or
resection of healthy tissues. The 3D-printed ears were
reported in 2014 (74). The main part was printed from poly-
caprolactone supported by PEG artificial layer and chondro-
cytes and adipocytes encapsulated in hydrogel. It was proven
that the composite structure satisfied expectations for both the
anatomy and geometry of the native ear. Fabrication of low
cost soft tissue prostheses was described by He, Xue and Fu
who applied Scanning Printing Polishing Casting (SPPC) to
manufacture artificial ear (75). The tissue casting mold was
prepared on the basis of 3D scan, chemically polished and
casted with medical grade silicon. The fabrication of smooth
prosthesis was estimated to cost ca. $30. Nasal prosthesis was
obtained by Unkovskiy et al. who printed two silicon-based
prostheses and applied post-process sealing and coloring (76).
Both of obtained prostheses fitted well into the patient’s defect
and set passively in position and both showed an acceptable
adaptation to the adjacent skin.
The clinical benefits of 3D printing is also noticeable in the
field of implantable medical devices. Nylon-based uretic stents
and laparoscopic trocars were printed and successfully devel-
oped in a female cadaver and in vivo porcine model (77). While
they fit the size of patients ureter, they exhibit some functional
challenges resulted from limitations of currently available
printers and materials.
The procedure of manufacturing of implants is usually
based on digital images obtained using computed tomography
(CT) or magnetic resonance imaging (MRI). The Computed
Aided Design (CAD) is then conjugated with 3D printing and
tailor-made structures are manufactured layer by layer. Such
methodology can be particularly helpful for manufacturing of
non-standardized implants for pediatric patients as described
for tracheobronchomalacia treatment (78). Customized,
collapse-resistance PCL-based bioresorbable tracheal splint
was implanted in an infant.
Beside polymer-based implants, 3D-printed devices made of
metals were also reported to be successfully implemented. First
effort inmanufacturing of personalized titaniumplates implanted
after microwave ablation used in bone tumor around the knee
was described byMa et al. (79) The authors described the process
of implantation following tumor resection. The post-surgical
evaluation of implant parameters as well as knee functionalities
showed no fractures or loosening problems.Moreover, the mean
maximum flexion of the knees was improved. The use of 3D-
printed titanium plates was concluded as significant improve-
ment in the surgical removal of bone tumor. Another customized
implant was developed for the treatment of sternal tumor (80).
Titanium implant was printed using direct metal laser sintering
technology and applied for the reconstruction of chest wall
defects. It was found to reduce morbidity and being beneficial
for the patient in terms of optimal function and structural chest
configuration after resection.
Models for Surgical Planning and Training, Phantoms
Medical phantoms stay as highly demanded structures sup-
porting the diagnosis and treatment of many diseases. While
image-driven surgery has been widely used for decades, the
need for rendering digital images has grown. The use of ad-
ditive manufacturing of models enables more accurate diag-
nosis, better evaluation and assessment of the pathological
changes as well as visualization of patient-specific organ anat-
omy. The preoperative planning significantly increases the
amount of information beyond individual organ features what
reduces the complications and patient loss (81). Thus, educa-
tion and surgical planning is believed to be one of the most
investigated field of 3D printing technology.
One of the example of using 3D-printed medical models is
manufacturing of liver models. The growing demand for
transplantations combined with the limited number of cadav-
eric livers increased the need of using the organ from healthy
donors. The preoperative identification of the anatomy of
vascular system and biliary tract can increase the safety of both
donor and recipient. Transparent models with appropriate
volume and color-coded vasculature was described in 2013
by Zein and coworkers (82). They prepared six models of
livers of 6 patients and demonstrated identical anatomical
and geometrical features between printed and native organs.
The 3D printing enables to plan the operation of resection of
tumor as described in patient with colorectal liver metastasis
(83). The CT scans were used to visualize the 3D anatomy of
patient’s liver, and organ contour-defining parts, blood vessels
as well as the tumor were printed. The model was then divided
into 4 parts due to the printer limitations. Multilayered struc-
ture was assembled and filled with silicone. The production of
resulted life-sized liver model with a transparent parenchyma,
color-coded vascularization and tumor inside was estimated to
cost less than $150. The patient underwent successful subse-
quent laparoscopic right hemihepatectomy. Another example
of preoperative planning based on 3D-printed phantoms is
modelling of renal malignancies (84). Stereolithography addi-
tive manufacturing was applied to manufacture 5 physical
phantoms of clear translucent renal units with red translucent
suspected malignancies. All patients underwent successful par-
tial nephrectomy.
Silicon models of kidney, renal pelvis and ureter were de-
veloped in order to train pediatric laparoscopic pyeloplasty
(85). Smaller workspace, finer sutures and more delicate tis-
sues in comparison with adults make this operation challeng-
ing thus training is highly demanded. Printed models were
tested with medical-imaging modalities such as magnetic
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resonance imaging, and 2D and 3D ultrasound. They were
concluded to be useful in image-guided tumor resection or as
platforms for surgical robotics. Moreover, the cost of produc-
tion did not exceed $100 and several hours of labor.
Recently, additivelymanufacturedmodels have been intro-
duced into cardiology, especially concerning the teaching of
congenital heart disease affected 1–2% of the world’s popula-
tion and being the leading cause of mortality among infants in
the US. These pediatric models have tremendous educational
value, demonstrate complex anatomical concepts such as
double-outlet right ventricle, malalignment-type ventricular
septal defects and the spectrum of heterotaxy syndromes (86).
Aortic diseases treatment is easier due to the 3D-printed
models that precisely reproduce aortic diameters and anatomy
(87). Additive manufacturing of phantoms has been successfully
introduced in patients with cardiac tumors or hypertrophic car-
diomyopathy where the lesion size is the key parameter deter-
mining the selection of the surgical strategy, i.e. partial or total
resection and heart transplant. This methodology has been
implemented in the total resection of right ventricular.
Implementation of 3D models is believed to provide rapid un-
derstanding of anatomical heart defects, including complex
phenomena such as criss-cross atrioventricular connections (88).
The rising amount of patients suffering from degenerative
diseases was also a problem addressed by additive manufac-
turing. Marks and coworkers showed 3D–printed brain in
several stages of Alzheimer’s disease as an educational materi-
als able to facilitate understanding of progressive degenerative
changes in cerebral cortex and hippocampus (89). MRI
images of brains of 5 patients in different clinical categories
were captured and printed from 3D structures rendered after
segmentation. The time of printing of each model varied from
15 to 20 h. The authors concluded that their models cannot be
used for diagnosis but only for education purpose so far as
some parameters need to be validated.
Bioprinting and Organs-on-Chip
Aging-, disease- or accident-related organ failures are a seri-
ous medical problems in recent year. While transplantation
serves as frequently used medical procedure, there is still the
risk of rejection and lifelong immunosuppressant-base thera-
py. Thus, regenerative medicine has searched for a better
solution. Recently, fabrication of multilayer object made from
soft biological materials such as living cells is believed to be
one of the most challenging and most promising technology.
The future of patient-centered medicine is now explored in
term of the development of biological constructs that are able
to restore tissue architecture and functions (90).
So far, additive manufacturing has been mainly utilized for
preparation of tissue construct such as cartilage, bone, blood
vessels, liver, kidneys or heart tissue. Bioink containing algi-
nate and nanocellulose was used to obtain structures
representing cartilage tissue (91). A homogenous distribution
of the cells was observed in printed material, however the
shear forces and cross-linking affected cell viability. Rapid
prototyping technology was also applied to utilize liver con-
struct. A modular gelatin and hyaluronic acid-based hydrogel
was used as a liver-specific bioink containing primary liver
spheroids (92). Biofabricated tissue constructs exhibited high
cell viability and ability to mimic in vivo liver functions.
To decrease the risk of rejection of 3D-printed construct au-
tologous source of cell can be used. They may be either taken
during biopsies or differentiation of autologous stem cells. The
3D-printed mesenchymal stem cell laden was described in the
treatment of myocardial infarctions due to the ability of the cells
to reduce the myocardial fate of postinfarction collagen deposi-
tion and scar tissue formation (93). However, therapeutic efficacy
is limited by restricted transport of cell-secreting therapeutic cyto-
kines at the implantation site. The developed cross-linked poly(-
ethylene glycol) dimethacrylate-based microchanneled hydrogel
patchwas found to effectively remove gel−tissue interface being a
physical barrier for biomolecular transports thus facilitating the
transport of cytokines.
Recently, numerous studies have been addressed to the
high integration and dynamic changes in cell environment
that affect tissue functions. Thus, microfluidics-based cell cul-
ture platform has been developed as an effective experimental
tool in bioengineering of organs. A 3D-printed liver on-a-chip
platform was developed using HepG2 and HUVEC cells and
poly(ε-caprolactone) as a platform (94). One-step fabrication
with heterotypic cell types and significantly enhanced func-
tions of liver-on-chip was described. Microfluidics was also
applied to print nervous system-on-chip as described by
Johnson and co-workers as a model for the study of viral
infection in the nervous system (95). Micro-extrusion 3D
printing was utilized to manufacture microchannels for axonal
alignment and compartmented chambers for cell isolation.
The authors demonstrated in vitro functionality of personalized
3D-printed model and marked future perspective in the de-
velopment of the treatment of neurological disorders.
Among numerous successful examples of printed bio-based
objects, bioprinting still faces several problems. One of the
most important issue is long-term viability of the cells.
Another one is control of cell proliferation in order to provide
sufficient amount of functional and supporting cells and tissue
homeostasis. The choice of cell type is also important as they
need to be able to reconstruct organ building blocks of various
function, architecture and size. Moreover, the tissues used in
3D printing should be able to survive pressure and shear stress
during printing, presence of harmful chemical compounds
and nonphysiological pH. Beside aforementioned conditions,
also scaffold material should meet given criteria such as bio-
compatibility, non-toxic by-products, appropriate mechanical
and structural properties as this can affect cell migration, ad-
hesion and proliferation (96).
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4th Dimension of Printing
Considerable progress that has been made in the field of ad-
ditive manufacturing led to the invention of smart 3D-printed
materials able to change their shape and properties upon ex-
ternal stimuli over time. The so called 4D printing technology
that considers manufacturing of shape memory materials, self-
evolving structures and actuators for biorobotics has attracted
considerable attention in recent years (97).
One of the earliest example of simple programmable mater
is so called Bmechanical protein^manufactured inMIT. These
millimeter-size single-strain components were able to self-
assembly into the letters MIT while the flat surfaces folded into
a cube (98). More complex self-evolving materials were devel-
oped by Ravil who described 3D manufacturing of linear and
ring stretching primitives as well as ring primitive composed of
dynamic segments that reacts in a different way when exposed
to water (99). The authors proved that self-deforming multi-
purpose structures become one of the emerging technology.
4D printing has been also applied in the field of biomaterial
manufacturing including biomedical devices, drug delivery
and tissue engineering. The biomimetic ink containing cellu-
lose fibril embedded in hydrogel matrix that exhibited local-
ized swelling anisotrophy after immersion in water was de-
scribed by Gladman (100). The authors described manufac-
turing of a series of shape-morphing systems that can be used
in utilizing smart textiles or biomedical devices. The additive
manufacturing of dynamically reconfigurable materials with
tunable functionality was concluded to Bopen a new avenues
for creating designer shape-shifting architectures for tissue en-
gineering, biomedical devices, soft robotics and beyond^.
The 3D printing of stimuli-responsive materials has been
also investigated in term of thermoresponsive hydrogels as they
can be used to create drug delivery systems releasing the active
compound upon thermal trigger at the first stage of inflamma-
tion. Poly(N-isopropylacrylamide) (PNIPAAm) hydrogel dem-
onstrating the temperature-dependent swelling behavior was
printed by means of projection micro-stereolitography. It was
described as a promising material for further studies in the field
of drug delivery vehicles (101). The same idea was presented by
Ge et al. who described the properties of objects printed with
tailorable shape memory methacrylate-based polymers.
Obtained smart gels exhibited different thermomechanical be-
havior what was believed to poses the great potential in the
development of scaffolds for cell growth and targeted delivery
of small molecules such as water or drugs (102).
The 3D-printed core-shell capsules exhibiting programmable
release was described by Gupta and co-workers. The capsules
had aqueous cores and poly(lactic-co-glycolic) acid (PLGA) shells
loaded with plasmonic gold nanorods which provided selective
rapturing of the capsules upon laser irradiation. The capsules
were described as a proof of concept of the combination of ad-
ditive manufacturing and smart materials (103).
Biorobotics
Bio-inspired hybrid devices being able to mimic various bio-
logical functions has recently been of considerable attention
(104). The biorobots are constructed of artificial scaffold made
from polymer elastomers or hydrogels that support soft bio-
logical matter such as proteins, living cells or tissues (105).
They are more flexible than traditional robots and thus able
to perform various types of movement such as walking or
swimming and interact with surrounding environment.
Within those robots rotary machines that are usually associat-
ed with transformation of chemical energy from the hydrolysis
of ATP into work are the most inspiring (106). Cell-based
actuators are usually cultured on thin flexible substrate. The
contraction of the cells leads to film deflection and actuation as
shown using mammalian cardiac and skeletal muscle cells
(107).
Giving the advantages of 3D (bio)printing of tissues and
organs the biorobots are highly demanded as they serve as small
mechanical devices able to participate in tissue regeneration
and drug delivery. They may also help to understand the loco-
motive mechanism of microorganisms as described byWilliams
and coworkers. They invented the flagellar swimmer with long
tail and short head composed of polydimethylsiloxane (PDMS)
filament cultured with cardiomiocytes (108). Moreover, the
authors suggested that the method can be applied to other
homotypic cell types, such as optogenetic muscle cells or het-
erotypic cells types, such as turtle cardiomiocytes and fibroblasts
as well as neurons and muscle cells for sensing-based intelligent
swimming. Another examples relies on seeding cardiomiocytes
on PDMS membrane and formation of micro-spherical heart
pump being able to control the flow within a microchannel due
to the pulsatile motion of a diaphragm (109).
The biorobots are self-sufficient in energy and nutrients as
the cells can generate the power to drive the motion and
absorb sufficient components to maintain life processes.
Although the viability of cells and control of motility still
remains a challenge, some ideas to improve those factors have
been introduced so far. They include enhancing the contrac-
tion force of the cells by applying anisotropic alignment, in-
troducing electrical stimulation in order to control the rate of
contractions or manufacturing of stimuli-responsive robots by
incorporating light-sensitive cells (110). Manufacturing of bio-
robots by means of 3D bioprinting pave the way for the de-
velopment of robust medical devices of tailor-made architec-
ture and functionalities.
SUMMARY
The 3D printing of drug delivery systems and medical devices
serves as an attractive tool to produce customized product.
Since few years the concept of 3D-printed drug formulation
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quickly evolved and was directed to enhance therapy by
patient-centric medicine. The first FDA approval of drug
manufactured by 3D printing technology caused an excep-
tionally rapid development of studies on oral, oromucosal
and topical dosage forms. This promising technology offers
formulation flexibility that is difficult to achieve with the con-
ventional technological processes. Additional manufacturing
allows to prepare different kind of dosage forms with high
precision of API-excipients ratio, in totally new manner with
comparison to traditional pharmaceutical manufacturing.
The added value of the 3D printing is also opportunity to
create multifunctional drug delivery systems, multidrug devi-
ces and drug formulations for personalized therapy with ac-
celerated release characteristic. Therefore, future research
should prioritize the development of pediatric and geriatric
dosage forms in personalized dosing and dimension-specific
drug formulations to ensure desired therapeutic effect.
Increasing amount of drug development studies proves unde-
niable benefits of this technology but the full success will be
obtained after leading elaborated new dosage forms on an
industrial scale.
The introduction of additive manufacturing into a clinic
reduces the time and costs of medical treatment and improves
the success rate of surgeries. It may also lead to the development
of new surgical procedures, especially concerning these risky and
rarely performed. Moreover, 3D printing of highly mimetic
models of organs for surgical training can ease and shorten op-
eration time and decrease the intra-operative complications.
The use of living cells enables formation of biomaterials for
reproducing vascularized tissues that can be used for implan-
tation, drug screening as well as disease modelling and cancer
research. The development of biorobots opens a new scope of
the development of sensors relying on physiological changes
experienced by cells or even artificial immune system.
Giving all the advantages, additive manufacturing needs to
face several challenges in terms of design parameters control,
device performance, biocompatibility of printed material and
sterilization. Furthermore the fragile nature of printed objects,
especially cell-based combined with complex nature of man-
ufactured structures requires well-planned procedure.
However, all benefits for patients and overall healthcare sys-
tem provided by the implementation of 3D printing makes the
amount of required research leading to establishing the pro-
cess of customized products manufacturing reasonable.
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